Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetes Population in the U.K.

CAROLINE A. ABBOTT, PHD1
RAYAZ A. MALIK, PHD1
ERNEST R.E. VANROSS, FRCP2
JAI KULKARNI, FRCP2
ANDREW J.M. BOULTON, MD1

OBJECTIVE—To assess, in the general diabetic population, 1) the prevalence of painful neuropathic symptoms; 2) the relationship between symptoms and clinical severity of neuropathy; and 3) the role of diabetes type, sex, and ethnicity in painful neuropathy.

RESEARCH DESIGN AND METHODS—Observational study of a large cohort of diabetic patients receiving community-based healthcare in northwest England (n = 15,692). Painful diabetic neuropathy (PDN) was assessed using neuropathy symptom score (NSS) and neuropathy disability score (NDS).

RESULTS—Prevalence of painful symptoms (NSS ≥5) and PDN (NSS ≥5 and NDS ≥3) was 34 and 21%, respectively. Painful symptoms occurred in 26% of patients without neuropathy (NDS ≤2) and 60% of patients with severe neuropathy (NDS ≥8). Adjusted risk of painful neuropathic symptoms in type 2 diabetes was double that of type 1 diabetes (odds ratio [OR] = 2.1 [95% CI 1.7–2.4], P < 0.001) and not affected by severity of neuropathy, insulin use, foot deformities, smoking, or alcohol. Women had 50% increased adjusted risk of painful symptoms compared with men (OR = 1.5 [1.4–1.6], P < 0.0001). Despite less neuropathy in South Asians (14%) than Europeans (22%) and African Caribbeans (21%) (P < 0.0001), painful symptoms were greater in South Asians (38 vs. 34 vs. 32%, P < 0.0001). South Asians without neuropathy maintained a 50% increased risk of painful neuropathy symptoms compared with other ethnic groups (P < 0.0001).

CONCLUSIONS—One-third of all community-based diabetic patients have painful neuropathy symptoms, regardless of their neuropathic deficit. PDN was more prevalent in patients with type 2 diabetes, women, and people of South Asian origin. This highlights a significant morbidity due to painful neuropathy and identifies key groups who warrant screening for PDN.

Neuropathy is one of the most common long-term complications of diabetes and is the main initiating factor for foot ulceration, Charcot neuroarthropathy, and lower-extremity amputation (1). However, the quality and even quantity of epidemiological data on symptomatic diabetic neuropathy remain poor due to inconsistent definitions, poor ascertainment, and a lack of population-based studies. Of three large, clinic-based studies from Europe, the prevalence of diabetic polyneuropathy varied from 23 to 29% (2,4). In the BARI 2D cohort of 2,368 type 2 diabetic patients with coronary artery disease, the prevalence of diabetic peripheral neuropathy was 51% (5). However, in all of these studies, although neuropathy symptoms were assessed as part of the diagnostic definition of diabetic neuropathy, the prevalence of painful diabetic neuropathy (PDN) per se was not established. In our large, community-based survey of 9,710 predominantly type 2 diabetic patients derived from general practice in northwest England, the prevalence of at least moderate neuropathic deficits as defined by a neuropathy disability score (NDS ≥6) was 22% and at least moderate neuropathy symptoms as defined by the neuropathy symptom score (NSS ≥5) was 34% (6).

PDN is considered to be the cause of considerable morbidity and, under the auspices of the American Academy of Neurology, evidence-based guidelines have been published for the management of this difficult condition (7). However, there is a distinct paucity of robust, population-based epidemiological data on the prevalence and natural history of this condition, limited to a few small studies. Thus, in a small population-based study of 269 diabetic patients from Wales, whereas 64% reported pain, only 26% were confirmed to have PDN, but interestingly those with PDN had a significantly poorer quality of life compared with those with nonneuropathic pain (8). In a study of 350 diabetic patients from Liverpool, 13% of patients with PDN had never reported their symptoms to their treating physician and a further 39% had not received any treatment for PDN (9). In a recent study of 1,113 diabetic patients attending secondary care clinics across Turkey, whereas 62% had neuropathy based on abnormal nerve conduction and clinical examination, only 16% had neuropathic pain according to the Leeds Assessment of Neuropathic Symptoms and Signs score (10).

The natural history of PDN remains unclear, although in a small longitudinal study, 77% of 56 diabetic patients with painful neuropathy were found to continue with nonabating pain after 5 years (11). Although it has been suggested that painful symptoms abate with progressive worsening of neuropathy, this has not been supported by a study that has demonstrated equal prevalence of painful symptoms in those with mild compared with more advanced neuropathy (12). Therefore there is a significant lack of large, population-based data defining the
size of the neuropathic pain problem and attempting to provide some explanations toward pain etiology. We have had the unique opportunity to assess the follow-
ing in a large, community-based diabetic population: 1) the prevalence of painful neuropathic symptoms; 2) the relationship between neuropathic symptoms and severity of clinical neuropathy; 3) the differences in neuropathic symptoms between patients with type 1 and type 2 diabetes; and 4) the role of sex and ethnicity.

**RESEARCH DESIGN AND METHODS**—The North-West Diabetes Foot Care Study (NWDFTS), a population-based investigation of diabetes-related foot problems in the community health care setting, provided the study population (6). The study was approved by the local research ethics committees, general practitioner (GP)-based diabetes teams, and hospital-based diabetes teams in each district and was funded by the Department of Health. One full-time research podiatrist or research nurse was appointed to screen diabetic patients in the GP practices, diabetes centers, and hospital outpatient clinics for each district. At GP practices, the vast majority of patients were screened while attending for their annual review; others were screened while attending podiatry clinics. Remaining patients were invited to attend a special clinic at the practice, or the patient was visited residentially. Each patient was assessed once for symptoms and signs of peripheral neuropathy, peripheral vascular disease (less than or equal to two palpable pedal pulses), demographic data, and medical history during a short (20–30 min) screening session.

**Assessment of neuropathy**

Peripheral neuropathy was assessed as previously described (6). Neuropathic deficits in the feet were determined using the NDS, derived from inability to detect pin-prick sensation (using Neurotip), vibration (using 128-Hz tuning fork), and differences in temperature sensation (using warm and cool rods) plus Achilles reflex (using tendon hammer) (6).

**NSS**

Patients were asked about their experience of pain or discomfort in the legs. If the patient described burning, numbness, or tingling, a score of 2 was assigned; fatigue, cramping, or aching scored 1. The presence of symptoms in the feet was assigned a score of 2, the calves 1, and elsewhere a score of 0. Nocturnal exacerbation of symptoms scored 2 vs. 1 for both day and night and 0 for daytime alone. A score of 1 was added if the symptoms had ever woken the patient from sleep. The patients were asked if any maneuver could reduce the symptoms; walking was assigned a score of 2, standing 1, and sitting or lying down 0. The maximum symptom score was 9. The severity of symptoms was graded according to the NDS as follows: none (0–2), mild (3–4), moderate (5–6), and severe (7–9) (2). The NDS has been used as part of the assessment of PDN in several previous studies (2,9,11,13). We defined PDN as at least moderate symptoms with mild neurologic signs (NSS score ≥5 and NDS score ≥3) (9,11).

**Statistical analysis**

Variables were stratified into normal and abnormal categories, and χ² tests were performed for categorical data. Normally distributed, continuous data were tested using Student t test, whereas nonnormally distributed data were first analyzed using Kruskal-Wallis, followed by a Mann-Whitney U test. After obtaining 95% CIs, age-adjusted prevalence rate differences were evaluated between the diabetes type, sex, and ethnic groups. Logistic regression was used to obtain odds ratios (ORs) for neuropathy symptoms between the comparison groups. Modifiers of the ORs were entered into the final logistic regression models to determine which risk factors may account for symptom differences. Statistical package SPSS 16.0 was used to analyze data.

**RESULTS**—Over 4 years, our community-based screening program assessed 15,692 patients with diabetes within six health care districts of northwest England, representing ~60% of involved GPs’ diabetic patients (6,14). The majority (70%) of patients were screened while attending their diabetes annual review in primary care, with the remainder (30%) screened at referral sites in diabetes centers and hospital outpatient clinics.

Demographic and medical characteristics of the entire community-based diabetic cohort and type 1 and 2 diabetic subcohorts are given in Table 1. The patients with type 2 diabetes were substantially older than those with type 1 diabetes (63.6 ± 11.8 vs. 37.6 ± 12.9 years, respectively) and had a greater proportion of South Asian/African Caribbean patients (15.1 vs. 3.9%, respectively). Duration of type 2 diabetes was one-quarter that of the type 1 group (P < 0.0001). Type 2 diabetic patients were less likely to be current smokers (22 vs. 33%, P < 0.0001). Despite substantially greater levels of clinical neuropathy, peripheral arterial disease (PAD), and foot deformities in the type 2 diabetic patients, foot ulcer rates (past or present) were similar between the two groups (4.9 vs. 6.0%, respectively, P = 0.07). Paradoxically, lower limb amputation rate was significantly lower in type 2 compared with type 1 diabetic patients (1.2 vs. 1.8%, P < 0.05).

**Prevalence of painful neuropathy**

The distribution of neuropathy symptom severity within the entire cohort was as follows: no symptoms (NSS 0–2) = 52% (8,073/15,638), mild symptoms (NSS 3–4) = 14% (2,254/15,638), moderate symptoms (NSS 5–6) = 18% (2,780/15,638), and severe symptoms (NSS 7–9) = 16% (2,531/15,638). The overall prevalence of painful neuropathy symptoms (i.e., NSS ≥5) in this cohort was 34% (5,311/15,638).

**Relationship between neuropathy symptoms and clinical severity of neuropathy**

The prevalence of painful neuropathy symptoms in the presence of clinical neuropathy (PDN) (i.e., NSS score ≥5 and NDS score ≥3) for all patients was 21% (3,242/15,614). The distribution of increasing neuropathy symptoms in patient groups stratified by the severity of clinical neuropathy is given in Fig. 1. Sixty percent (3,797/629) of diabetic patients with severe clinical neuropathy (NDS >8) had painful neuropathic symptoms (NSS ≥5), whereas only 26% (2,060/8,016) of patients without clinical neuropathy (NDS ≤2) had painful symptoms. There was an emerging pattern of worsening clinical neuropathy scores associated with an increasing proportion of patients with more severe painful neuropathic symptoms (P < 0.0001), and there was a significant, positive correlation between NSS and NDS (r = 0.24, P < 0.0001). This relationship between signs and symptoms was stronger in type 1 (r = 0.37, P < 0.0001) than type 2 diabetic subjects (r = 0.22, P < 0.0001).

**Type 1 versus type 2 diabetes**

Painful symptoms (NSS ≥5) were more prevalent in type 2 (35.0% [4,962/14,166]) versus type 1 (22.7% [303/1,334], P < 0.0001) diabetic patients, as was PND (21.5% [3,039/14,144] vs. 13.4% [178/1,333], respectively, P < 0.0001). The
risk of painful neuropathy symptoms in type 2 diabetic patients was 83% higher than in type 1 patients (OR = 1.8 [95% CI 1.6–2.1], P < 0.0001); this risk doubled after adjusting for differences in age and diabetes duration (OR = 2.1 [1.7–2.4], P < 0.0001). When examining patients with moderate to severe clinical neuropathy (i.e., NDS $\geq$6) only, the age- and diabetes duration–adjusted risk of painful symptoms in type 2 versus type 1 diabetic patients was still significantly greater (OR = 1.8 [1.2–2.5], P < 0.0001).

### Age effect

Increasing age was very weakly associated with NSS severity in the entire population (r = 0.083, P < 0.0001); however, this relationship was stronger in type 1 (r = 0.20, P < 0.0001) than type 2 diabetes (r = 0.022, P = 0.008). Indeed, increasing age categories in type 1 diabetic patients showed an almost doubling in prevalence of painful symptoms (NSS $\geq$5) (aged $\leq$35 years, 17.2%; 35–54 years, 26.4%; 55+ years, 33.1%; P < 0.0001), with a similar, but less marked, association in type 2 diabetic patients (aged $\leq$35 years, 30.6%; 35–54 years, 32.7%; 55+ years, 35.7%; P < 0.01).

### Effect of diabetes treatment

Insulin use versus oral hypoglycemic agents (OHAs) and/or diet had no effect on painful neuropathy symptoms, i.e., 33% (1,085/3,272) of patients using insulin had NSS $\geq$5 compared with 34% (4,206/12,303) of patients treated with diet and OHA (P = 0.27). However, when treatments were examined individually, a broader picture emerged.

### Table 1—Demographic and medical characteristics of patient cohorts

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total population</th>
<th>Type 1 diabetes</th>
<th>Type 2 diabetes</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>15,692</td>
<td>1,338/15,544 (8.6%)</td>
<td>14,206/15,544 (91.4%)</td>
<td>—</td>
</tr>
<tr>
<td>Male</td>
<td>8,468/15,684 (53.9%)</td>
<td>750/1,338 (56.1%)</td>
<td>7,631/14,203 (53.3%)</td>
<td>0.10</td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.4 ± 14.0</td>
<td>37.6 ± 12.9</td>
<td>63.6 ± 11.8</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Duration diabetes (years)</td>
<td>5 (2–10)</td>
<td>17 (10–26)</td>
<td>4 (2–10)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White European</td>
<td>13,409/15,692 (85.5%)</td>
<td>1,283/1,338 (96.0%)</td>
<td>12,015/14,206 (84.6%)</td>
<td></td>
</tr>
<tr>
<td>South Asian</td>
<td>1,866/15,692 (11.9%)</td>
<td>42/1,338 (3.1%)</td>
<td>1,791/14,203 (12.6%)</td>
<td></td>
</tr>
<tr>
<td>African Caribbean</td>
<td>371/15,692 (2.4%)</td>
<td>11/1,338 (0.8%)</td>
<td>357/14,203 (2.5%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>46/15,692 (0.2%)</td>
<td>2/1,338 (0.1%)</td>
<td>43/14,203 (0.3%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Diabetes treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diet only</td>
<td>4,643/15,622 (29.7%)</td>
<td>—</td>
<td>4,601/14,163 (32.5%)</td>
<td></td>
</tr>
<tr>
<td>OHG + diet</td>
<td>7,696/15,622 (49.3%)</td>
<td>—</td>
<td>7,637/14,163 (53.9%)</td>
<td></td>
</tr>
<tr>
<td>Insulin (±OHG)</td>
<td>3,283/15,622 (21.0%)</td>
<td>1,337/1,338 (100.0%)</td>
<td>1,925/14,163 (13.6%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Overt nephropathy</td>
<td>440/15,274 (2.9%)</td>
<td>58/1,308 (4.4%)</td>
<td>379/13,841 (2.7%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Impaired vision</td>
<td>1,700/15,455 (11.0%)</td>
<td>108/1,319 (8.2%)</td>
<td>1,574/14,006 (11.2%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>6,568/15,632 (42.0%)</td>
<td>626/1,335 (46.8%)</td>
<td>5,895/14,156 (41.4%)</td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>3,581/15,632 (22.9%)</td>
<td>445/1,335 (33.3%)</td>
<td>3,111/14,156 (22.0%)</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>5,483/15,632 (35.1%)</td>
<td>264/1,335 (19.7%)</td>
<td>5,197/14,156 (36.6%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Alcohol (≥7 units/week)</td>
<td>6,998/15,474 (45.2%)</td>
<td>877/1,323 (66.3%)</td>
<td>6,074/14,020 (43.3%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Clinical neuropathy</td>
<td>3,333/15,659 (21.3%)</td>
<td>217/1,337 (16.2%)</td>
<td>3,077/14,183 (21.7%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Foot deformities</td>
<td>4,699/15,600 (30.1%)</td>
<td>204/1,335 (15.3%)</td>
<td>4,495/14,126 (31.5%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>3,139/15,664 (20.0%)</td>
<td>139/1,337 (10.4%)</td>
<td>2,957/14,186 (20.8%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Foot ulcer history</td>
<td>774/15,484 (5.0%)</td>
<td>80/1,331 (6.0%)</td>
<td>684/14,015 (4.9%)</td>
<td>0.070</td>
</tr>
<tr>
<td>Lower-limb amputation history</td>
<td>191/15,422 (1.2%)</td>
<td>24/1,327 (1.8%)</td>
<td>164/13,955 (1.2%)</td>
<td>0.045</td>
</tr>
</tbody>
</table>

Data are mean ± SD, n (%), or median (25th–75th percentiles); P values for type 1 vs. type 2.

---

Figure 1—Percentage prevalence of neuropathic symptoms in 15,659 diabetic patients characterized by their level of peripheral clinical neuropathy.

---

Abbott and Associates
Painful diabetic neuropathy in U.K. community

Symptoms were most prevalent in patients treated with OHA (37.3%) compared with insulin (33.2%) or diet alone (29.1%) (P < 0.0001). Restricting the analysis to patients with clinical neuropathy, painful symptoms were most prevalent in the insulin-treated group > OHG group > diet-only group (54.7, 50.6, and 42.1%, respectively; P < 0.0001).

**Effect of sex**
A significantly greater proportion of females (38% [2,732/7,212]) than males (31% [2,578/8,423]) reported painful neuropathy symptoms (P < 0.0001), despite fewer females than males having clinical neuropathy (NDS ≥6) (19 vs. 23%, P < 0.0001). PDN (NSS ≥5 and NDS ≥3) was, similarly, more prevalent in females than males (23 vs. 19%, respectively, P < 0.0001). After adjustments for age, diabetes duration, and differences in clinical neuropathy, women still had a 50% increased risk of painful symptoms compared with men (OR = 1.5 [95% CI 1.4–1.6], P < 0.0001).

**Effect of ethnicity**
Despite a lower unadjusted prevalence of clinical neuropathy (NDS ≥6) in South Asians (14%) compared with Europeans (22%) and African Caribbeans (21%) (P < 0.0001), painful neuropathy symptoms (NSS ≥5) were significantly and, conversely, greater in South Asians (38%) compared with Europeans (34%) and African Caribbeans (32%) (P < 0.0001). Greater neuropathy symptoms in South Asians, however, were only evident in patients without clinical neuropathy (i.e., NDS ≥5 and NDS ≥2: South Asians 19% [352/1,845], Europeans 13% [1667/13,354], African Caribbeans 10% [36/370]; P < 0.0001), whereas PDN (NSS ≥5 and NDS ≥3) was similarly prevalent in all ethnic groups (21% [2,803/13,354], 19% [349/1,845], and 22% [80/370], respectively; P = 0.11). After adjustments for age and diabetes duration, South Asians without significant clinical neuropathy were still 50% more likely to have painful neuropathy symptoms compared with other ethnic groups (OR = 1.5 [95% CI 1.3–1.6], P < 0.0001).

**Conclusions**—We have shown that one-third of all patients with diabetes in the community have painful neuropathic symptomatology, regardless of whether they have clinical neuropathy. These data show a higher prevalence of painful neuropathic symptoms than previously reported in two small population-based studies (9,11). In a recent study using the validated DN4 (a clinician-administered neuropathic pain diagnostic questionnaire), the prevalence of PDN in 1,039 diabetic patients in secondary care was found to be 65% (15). Our current data indicate a large morbidity for neuropathic pain in a community-based diabetic population. They also challenge the dogma that painful neuropathic symptoms improve as the severity of neuropathy worsens and provide support for a previous study that actually demonstrated comparable prevalence of painful neuropathy in diabetic patients with mild and more severe neuropathy (12). Furthermore, approximately one-quarter of our patients without clinical neuropathy on examination had significant painful neuropathic symptoms, indicating the large disparity between signs and symptoms. But of course even patients with impaired glucose tolerance and no apparent neuropathy develop painful neuropathic symptoms and small nerve fiber damage (16). This emphasizes the need to ask all patients about the occurrence of painful neuropathic symptoms, not just those who have clinical neuropathy. Painful symptoms were twice as prevalent in type 2 versus type 1 diabetic patients, even after adjusting for differences in age, neuropathy, PAD, and other known risk factors for neuropathic pain (17). These data are consistent with a previous study that demonstrated a higher prevalence of clinical neuropathy in type 2 compared with type 1 diabetic patients, assessed using a combination of the NSS and NDS (2). Previously, the prevalence of PDN has not been found to differ between type 1 and type 2 diabetes, although the proportion of patients with type 1 diabetes was very small (9,15). Women had a 50% increased risk of painful symptoms compared with men. This has also been demonstrated recently in a study from Saudi Arabia (15). This latter study demonstrated no ethnic differences for the incidence of PDN (15). In the current study, however, we demonstrate a significantly higher prevalence of painful neuropathic symptoms in South Asians compared with Europeans and African Caribbeans, with a 50% increased risk of neuropathic pain in South Asians in the absence of clinical neuropathy. Paradoxically, we have previously demonstrated a lower prevalence of both large and small fiber neuropathy (18), as well as incidence of foot ulceration (14), in South Asians.

The major strength of this epidemiological study, compared with others, is that it is substantially larger than any previously published study on the prevalence of PDN. Furthermore, it is community based and therefore reflects the magnitude of this problem in a non-selected cohort of diabetic patients. As this study was designed to be totally inclusive for community-based patients with diabetes, we did not exclude patients with neuropathic pain from an etiology other than diabetes, or attempt to identify pain from a different origin. We did not assess the duration of pain, hence the prevalence of chronic pain (≥6 months) could not be established. The use of medications for the treatment of neuropathic pain was not recorded. We used the NSS as it is relatively quick to administer and is weighted toward positive neuropathic symptoms in the lower limbs, consistent with PDN. Indeed, three key lower-limb symptoms that characterize neuropathic pain from nonneuropathic pain are tingling pain, numbness, and increased pain due to touch (19) and are incorporated in the NSS. Numbness or “cotton wool-like feeling” is a positive, identifiable, painful symptom described by patients and thus different to loss of sensation, which patients may or may not be aware of. These symptoms were captured by the NSS along with a measure of the distribution, presence of nocturnal exacerbation, and relieving factors.

The demonstration that one-third of all diabetic patients have significant tingling/shooting, burning pain, with or without numbness, in the lower limbs indicates a larger morbidity than previously established in relatively small and selective studies in the U.K. (9,11) and in a recent larger, but selected, population-based study from Germany (17). Our finding that one-quarter of community patients without clinical neuropathy have painful neuropathic symptoms implies that a large proportion of the diabetic community are being neglected in the treatment of their symptoms, and that classic neuropathic, lower-limb symptoms may well be inappropriately considered “nonneuropathic” if there are no concomitant signs of clinical neuropathy. Davies et al. (8) also showed that a significant proportion (7.4%) of subjects with PDN using the Toronto Clinical Scoring System had no clinical signs of neuropathy. We have extended this observation in a large cohort of patients and shown that ~40% of all patients without signs of neuropathy will have at least mild neuropathic symptoms.
To conclude, we have observed greater neuropathic pain levels in type 2 diabetes, in women, and in people of South Asian origin. These areas demand further investigation and also highlight key groups who may warrant screening for PDN.

Acknowledgments—Funding of the NWDFCS foot screening program was originally provided by the Department of Health.

No potential conflicts of interest relevant to this article were reported.

C.A.A. coordinated the study, monitored data collection, cleaned and analyzed data, and drafted and revised the manuscript. R.A.M. analyzed data and drafted and revised the manuscript. A.J.M.B. initiated and designed the project and drafted and revised the manuscript. E.R.E.v. and J.K. designed the project and revised the manuscript. A.J.M.B. initiated and designed the project and drafted and revised the manuscript.

The authors would like to thank all original members of the NWDFCS who implemented the foot screening and data collection.

References


